Sequencing or not sequencing multikinase inhibitors in kidney cancer: this is the dilemma

Main Article Content

Chiara Paglino *
Camillo Porta
(*) Corresponding Author:
Chiara Paglino | c.porta@smatteo.pv.it

Abstract

With the recent development of targeted therapies (Sorafenib, Sunitinib, Temsirolimus, Bevacizumab plus Interferon-a, Everolimus and now also Pazopanib) patients with advanced renal cell carcinoma (RCC) now have a wide range of treatment options, all of which have shown both relevant clinical activity and manageable safety profile. This abundance of active treatments, coupled with relatively limited information, we have gathered from registrative phase III trials have raised the question of how to use these agents optimally...

Downloads month by month

Downloads

Download data is not yet available.

Article Details